Ordinary promoter vaccines are the future fighting with COVID-19 infection, top genome experts says Kumar Jeetendra | March 15, 2021 Standard booster vaccines against the novel coronavirus will be needed because of mutations that make it more transmissible and better able to evade human immunity, the head of Britain’s attempt to sequence the virus’s genomes told Reuters. The novel coronavirus, which has killed 2.65 million individuals globally since it emerged in China in late 2019, …
Killing antibodies actuated by COVID-19 vaccines less successful against new variants Kumar Jeetendra | March 15, 2021 SARS-CoV-2, the virus that causes COVID-19, has mutated through the pandemic. New variants of this virus have arisen around the world, including variants that might possess increased capacity to spread or evade the immune system. Such variations have been identified in California, Denmark, the U.K., South Africa and Brazil/Japan. Recognizing how well the COVID-19 vaccines …
Study offers understanding into metabolic pathways hijacked by SARS-CoV-2 for viral replication Kumar Jeetendra | March 16, 2021 When SARS-CoV-2, the virus which causes COVID-19, infects a human cell, it quickly begins to replicate by seizing the cell’s existing metabolic machinery. The infected cells churn out thousands of viral genomes and proteins while halting the creation of their own sources. Researchers from Brigham and Women’s Hospital, Massachusetts General Hospital (MGH), and the Broad …
Vaccines may require regular updates as Covid develops, say researchers Kumar Jeetendra | March 27, 2021 A health worker checks the Covishied, a COVID-19 vaccine manufactured by Serum Institute of India, as she prepares to start vaccination against COVID-19 in Kathmandu, Nepal January 27, 2021. (Reuters/Navesh Chitrakar) Scientists have assessed the course of development of the novel coronavirus and predicted that COVID-19 vaccines currently in use across the world may need …
Small SARS-CoV-2 protein may have huge ramifications for future COVID-19 medicines Kumar Jeetendra | April 12, 2021 A very small protein of SARS-CoV-2, the coronavirus that gives rise to COVID-19, may have big implications for future therapies, according to a team of Penn State researchers. Using a novel toolkit of approaches, the scientists uncovered the first full structure of the Nucleocapsid (N) protein and discovered how antibodies from COVID-19 patients interact with …
Researchers enlighten how a few antibodies can viably disable ebolaviruses Kumar Jeetendra | April 18, 2021 Some survivors of ebolavirus outbreaks create antibodies that may broadly neutralize those viruses–and today , scientists at Scripps Research have illuminated how these antibodies can disable the viruses so efficiently. The insights might be helpful for developing effective treatments. Ebolavirus is a family of often-deadly viruses that includes Ebola virus and lots of lesser-known viruses …
FDA denies EUA for monoclonal antibody treatment bamlanivimab to treat patients with COVID Kumar Jeetendra | April 18, 2021 Now, the U.S. Food and Drug Administration revoked the emergency use authorization (EUA) that allowed for the investigational monoclonal antibody treatment bamlanivimab, when administered alone, to be utilized for treating mild-to-moderate COVID-19 in adults and certain pediatric patients. Based on its ongoing analysis of emerging scientific data, specifically the sustained increase of SARS-CoV-2 viral variants …
J Mitra Launches India’s First Covid-19 Neutralizing Antibody Test Kumar Jeetendra | April 29, 2021 New Delhi, 29th April 2021: J Mitra & Company, the global leader in the IVD space, has launched India’s first Covid-19 Neutralizing Antibody Microlisa Elisa Test its ongoing fight against the corona pandemic. The test kit has cleared all government parameters and received all necessary approvals, including Drug Controller General of India (DCGI) & successful …
Researchers develop experimental direct-acting antiviral treatment to treat COVID-19 Kumar Jeetendra | May 18, 2021 An international team of scientists from the Menzies Health Institute Queensland (MHIQ) at Griffith University and from City of Hope, a research and treatment center for cancer, diabetes and other life-threatening diseases in the U.S., have developed an experimental direct-acting antiviral therapy to treat COVID-19. Conventional antivirals reduce symptoms and help people recover earlier. Examples …
Mild cases of COVID-19 give enduring antibody, shows study Kumar Jeetendra | May 24, 2021 Months after recovering from mild cases of COVID-19, people still possess immune cells in their body pumping out antibodies against the virus that causes COVID-19, according to a study from researchers at Washington University School of Medicine in St. Louis. Such cells could persist for a lifetime, churning out antibodies all of the while. The …
Moderna looks for full FDA endorsement for its COVID-19 vaccine Kumar Jeetendra | June 1, 2021 American pharmaceutical company Moderna says it has begun the process to win full U.S. regulatory approval for the use of its COVID-19 vaccine in adults. Moderna announced on Tuesday it has begun a “rolling submission” to the Food and Drug Administration of data from its studies of the two-dose vaccine. Moderna’s vaccine already has been …
Pfizer jabs delivers less antibodies against Delta variation of Covid: Lancet study Kumar Jeetendra | June 4, 2021 People fully vaccinated with the Pfizer-BioNTech vaccine are likely to have more than five times lower levels of neutralising antibodies against the Delta variant first identified in India compared to the original strain, according to research published in The Lancet journal. The study also shows that levels of these antibodies that are able to recognise …
